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ABSTRACT  
Introduction: The generation of robust evidence has been emphasised as a priority for global health. 
Evidence generation spans a wide range of activities including clinical trials, surveillance programmes, and 
health system performance measurement. As resources for health care and research are limited, the 
desirability of research expenditure should be assessed on the same basis as other health care resources, i.e. 
the health gains from research must be expected to exceed the health opportunity costs imposed as funds 
are diverted to research rather than service provision.  
Methods: We developed a transmission and costing model to examine the impact of generating additional 
evidence to reduce uncertainties on the evolution of a generalised HIV epidemic in Zambia. 
Results: We demonstrate three important points. Firstly, we can quantify the value of additional evidence 
in terms of the health gain it is expected to generate. Secondly, we can quantify the health opportunity cost 
imposed by research expenditure. Thirdly, the value of evidence generation depends on the budgetary 
policies in place for managing HIV resources under uncertainty. Generating evidence to reduce uncertainty 
is particularly valuable when decision makers are required to strictly adhere to expenditure plans and when 
transfers of funds across geographies/programmes are restricted. 
Conclusion: Better evidence can lead to health improvements in the same way as direct delivery of health 
care. Quantitative appraisals of evidence generation activities are important and should reflect the impact 
of improved evidence on population health, evidence generation costs, and budgetary policies in place. 
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KEY QUESTIONS 
What is already known about this topic? 
x Strategies for HIV investment rely on the availability of relevant evidence but this evidence is 
subject to uncertainty.  
x The value of additional evidence to resolve uncertainties has typically ignored the impact of 
budgetary policies when managing programme delivery. 
What are the new findings? 
x The conceptual modelling framework shows how to value evidence generation activities to 
improve decisions made within a vertical HIV disease programme in the face of uncertainty and 
realistic budgetary policies, and compares this to the health opportunity costs of research 
expenditure. 
x The value of evidence generation activities vary across settings that use different budgetary policies, 
which has important implications for research prioritisation decisions.  
How might this influence practice? 
x Decision makers charged with prioritising evidence generation activities can maximise population 
health outcomes in the same way as other health care investment by taking account of the health 
opportunity costs of research expenditure.  
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INTRODUCTION 
HIV/AIDS remains one of the leading causes of death and disability in much of eastern and southern 
Africa.1 Access to effective HIV treatments is increasing2 and recent scientific advances have provided 
interventions that are effective in reducing the risk of HIV acquisition and transmission.3 The Joint United 
Nations Programme on HIV/AIDS (UNAIDS), the Global Fund to Fight AIDS, Tuberculosis and Malaria, 
and the U.S. President's Emergency Plan for AIDS Relief have emphasised that effective interventions 
should be prioritised for use in populations in which they deliver most benefit.4-7 Survey and mapping 
methods are now used in many countries to identify areas of high-risk behaviour and high prevalence in 
order to target interventions to where they offer most benefit.8   
Cost-effectiveness analysis can support the development of D´IRFXVHGµVWUDWHJ\IRU+,9LQYHVWPHQW9, 10 
whereby an allocation of resources across risk-groups, geographical areas, time11 and among competing 
HIV prevention and treatment strategies is chosen that maximises the health attainable, given the available 
resources. A focused strategy can lead to greater health impact than a strategy in which the same mix of 
interventions is used uniformly across a highly heterogeneous epidemic.10  
The development of a strategy for HIV investments relies on the availability of relevant and reliable 
evidence. This typically includes evidence relating to the epidemiology and natural history of HIV and how 
this varies across different populations, the impact of alternative interventions on these processes, the costs 
of interventions and other health care costs.  This evidence typically comes from a wide range of sources 
including clinical trials, surveillance studies, long-term observational studies, costing studies and quality of 
life surveys. Evidence is often synthesised using decision modelling in order to provide estimates of the 
costs and outcomes associated with different policy choices over a suitable time frame.9  
The costs and health gains from local HIV services are inherently uncertain as the underlying evidence base 
and modelling approach are subject to uncertainty. This uncertainty has two implications.  
Firstly, the HIV investment strategy that was expected to maximise population health from available 
resources may not turn out to be the optimal course of action. This implies that if we had better information 
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when planning the HIV investment strategy, better health outcomes could be achieved from available 
funding.  
The second implication of uncertainty is that budgets allocated to fund specific services in specific 
populations or geographies may not align with the prevailing situation on the ground. For example, HIV 
prevalence or costs of care may be higher than expected, so planned levels of population coverage for 
services may not be attainable with available funds. Where decision makers face hard budget constraints 
that limit their ability to accommodate cost over-runs, they will require a budgetary policy to be in place in 
order to manage the cost variances. This implies that if we had better information when planning the HIV 
investment strategy, the likelihood of deviations from the strategy could be reduced. This represents an 
important benefit of reducing uncertainty for real-world resource allocation decisions12 but has been largely 
overlooked so far in quantitative appraisals of evidence generation activities.  
In this study we show the health benefits of evidence generation activities when both of these implications 
of uncertainty are considered. We show the importance of weighing these health benefits against the 
opportunity costs associated with allocating resources to research rather than service provision. Finally, we 
show how the value of evidence generation activities depends on the budgetary policy in place.  
 
METHODS 
Overview 
A conceptual modelling framework is used to explore the population health implications of investing in 
evidence generation activities. This model is based upon features of a generalised HIV epidemic in sub-
Saharan Africa and the policy response to this. We use Zambia as a case study to illustrative the principles 
of the analyses required, and the qualitative implications of alternative courses of action. The model is a 
simplified representation of HIV epidemiology in Zambia, the HIV prevention and treatment investment 
opportunities available, and the available options for policy makers responding to uncertainty. For these 
reasons the results should not be interpreted as providing an accurate quantification of different policy 
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options for Zambia but instead are intended to demonstrate qualitative findings in a relevant setting. A 
simple transmission model is used to quantify health effects.  The aim of the national HIV programme is 
to allocate a fixed budget to different interventions and across Zambian provinces to maximise population 
health (expressed in terms of quality-adjusted life years, QALYs).  .The interventions considered are (i) 
ART in individuals with HIV who present for care due to ill health and who typically have CD4 counts 
EHORZ  KHQFHIRUWK ´ODWH $57µ LL YROXQWDU\ PHGLFDO PDOH FLUFXPFLVLRQ LQ WKRVH ZLWKRXW +,9 
LQIHFWLRQ´FLUFXPFLVLRQµDQGLLL$57LQLQGLYLGXDOVZLWK+,9ZKRDUHLGHQWLILHGYLDRXWUHDFKWHVWLQJ
DQGZKRW\SLFDOO\KDYH&'FRXQWVDERYH´HDUO\$57µ The first stage of national HIV planning 
involves determining the optimum coverage level of the interventions in each region in order to maximise 
the expected (average) health outcomes based on currently available information (i.e. before the 
implications of uncertainty XQIROG  7KLV UHSUHVHQWV WKH ¶SODQQHG· +,9 LQYHVWPHQW VWUDWHJ\  7KLV LV
developed under an additional requirement that late ART is considered an imperative2 and decision makers 
are constrained to scale up provision of late ART until all those with late stage disease receive it. Investment 
in circumcision and early ART is only pursued if there is sufficient funding to support wide scale provision 
of late ART.   
The second stage involves application of a policy response to uncertainty. Under current information we 
initially assume that a regional policy operates whereby once the HIV investment strategy has been set and 
budgets disbursed to regions, the regions must adhere to the intervention budgets allocated. This reflects 
the fact that recent years have seen a move towards budgets being held locally by decentralized levels of 
government or non-governmental service providers.  
To assess the maximum value of investing in evidence generation activities, we assess the health that could 
be achieved if current uncertainties were completely eliminated and the values of the model parameters 
were known i.e. the health that could be achieved if we had perfect information. Although in reality further 
data collection will not resolve all uncertainty, the health generated under perfect information can be 
compared to the health attained with current information to establish the maximum expected health gains 
associated with evidence generation activities. This provides the starting point to determine whether 
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additional data collection is worthwhile and whether spending should be devoted to data collection or 
service delivery.   
We then show the impact of the costs of research on the net health benefits of evidence generation 
activities. These are quantified by comparing the health achieved under current information with the health 
achieved with perfect information but with a reduced intervention budget (to reflect the resources that must 
be spent on research). This comparison can be made using different estimates of the resources that must 
be spent on research. We also estimate the maximum that can be spent on research before it becomes net 
health reducing i.e. the monetary value of research. This can then be used as a benchmark to compare to 
the costs of the research to determine whether the research is potentially worthwhile.  
Finally, we examine how the budgetary policy, by modifying the health attained under current information, 
impacts upon the health benefits of evidence generation. We examine two alternatives to the regional policy 
response: the national policy and the contingency fund policy, which alongside the regional policy are 
intended to represent the spectrum of approaches operating in countries in sub-Saharan-Africa.  
Model description  
A transmission model was used to predict the impact of interventions on the course of the HIV epidemic 
over a 15-year period (2015-2030). We modelled outcomes in adults aged 15-49 in nine different provinces 
of Zambia with populations ranging from 400,000 to 1.1 million individuals. Each region represented a 
locality for which a HIV budget can be administered by a government or non-government organisation. 
The regions differed in HIV prevalence, which ranged from 5.4% to 18.2%, and the baseline proportion of 
individuals entering the population who were circumcised, which ranged from 1.6% to 72.6% of men; this 
resulted in differences across regions in the costs and effects of investments. Individuals entered the 
population without infection at age 15. A proportion of individuals who do not have HIV faced the risk of 
infection. Newly infected individuals enter early-stage infection and progress to late-stage infection which 
worsens their quality of life and prognosis.  Full details on study methods are available in the Supplementary 
Appendix.  
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Epidemiology and intervention effects 
Province-level population data, HIV prevalence and rates of circumcision were obtained from a previous 
epidemiological model and reflect the parameter values obtained following calibration to a range of key 
data sources, for further detail see McGillen et al.15 Natural history parameters were taken from a range of 
sources and intervention effects reflect findings from key meta-analyses.20, 21 Late ART reduces transmission 
rates, reduces mortality and improves quality of life, circumcision reduces the risk of acquiring infection, 
while early ART removes the possibility of progression to late-stage disease and reduces transmission. 
Intervention coverage was assumed constant over time. Regardless of the selected investments, a 
proportion of the population were assumed to be circumcised independently of the HIV circumcision 
programme, and provision of ART was scaled up to 80% coverage of individuals with late-stage infections 
prior to 2015 (considered to reflect universal coverage2 amongst this population). 
Uncertainty 
Uncertainties in HIV prevalence in each region, the impact of circumcision and ART on the risk of 
transmission, and the costs of ART and circumcision delivery were included in the model. Uncertainties 
were included in the model by assigning a statistical distribution to each uncertain quantity. Different 
distributions were assigned to prevalence in each region to reflect difference in prior knowledge regarding 
geographical differences in HIV epidemiology. The same distributions were used across regions for the 
other uncertainty parameters. The uncertainty reflects the fact that the true values of these quantities are 
unknown. For example, an estimate of HIV prevalence for a particular geographical area may be available 
from a household survey. Nonetheless, actual prevalence may differ from this estimate as the survey sample 
may have been small and therefore by chance have contained more or less individuals with HIV than the 
target population, or the sample may not fully match the characteristics of the target population.8  
Economic analysis  
Costs per circumcision, per year on ART and of HIV testing were included and reflect comprehensive large 
scale costing studies conducted in Zambia. 23-27 Costs were assumed to decrease according to the scale of 
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production but increase at high coverage levels due to the need for outreach activities.28, 29 QALYs were 
estimated by allocating disability adjusted life year weights30, 31  according to the distribution of modelled 
individuals across different health states. The consequences for population health of generating additional 
evidence are evaluated at national HIV budgets up to $23 per capita per annum (pcpa) or ~$200 per 
individual with HIV, beyond this point all investment opportunities considered within the model had been 
exhausted. .  
Health outcomes under different informational and budgetary scenarios 
All policies involved a first stage in which the planned HIV investment strategy was developed to maximise 
health given the available resources and based upon currently available data (Figure 1). This provided a plan 
for the coverage levels for each intervention in each region, and how resources should be allocated between 
regions. 
Under current information and a regional policy decision makers spent what they initially planned on each 
intervention in each region. They did not reallocate resources across interventions or have means by which 
to extend their total regional funds beyond those allocated. This ensured regional spending did not exceed 
the budget; however, it did not guarantee that regions were able to achieve the coverage planned. For 
example, if HIV prevalence was higher than expected, available funds may not be sufficient to deliver on a 
commitment to universal late ART coverage. If the funding for an intervention within a region exceeded 
that required to deliver the planned coverage level, then intervention coverage was scaled up to the point 
at which the allocated funds were exhausted unless this exceeded the maximum feasible coverage level, in 
which case coverage was capped at this maximum and any further funds that were allocated to that 
intervention were used ineffectively. This was considered to be a close model of the challenges faced when 
managing funds under uncertainty. This simulates the situation whereby once funds are committed to a 
region and intervention programme, it is not possible for those funds to be transferred to another region 
or intervention. 
Under perfect information the values taken by the model parameters are known and the HIV investment 
strategy can therefore be revised for each realisation of uncertainty. This ensures that the investment 
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strategy delivers the maximum health from available resources, and removes the possibility of cost variances 
as budgets are always set correctly. The difference between the health achieved with perfect information 
(parameter values known, no uncertainty) and the health achieved under current information (parameter 
values subject to uncertainty with a regional policy response to the uncertainty) represents the expected 
maximum health benefits of evidence generation activities (i.e. the expected value of perfect information, 
EVPI).32  
Under current information and a national budgetary policy total spending across regions was required to remain 
within the national HIV budget but funds could be transferred between regions to support implementation 
of the planned investment strategy.  If the total cost of the investment strategy exceeded the national HIV 
budget then expenditure was scaled down by the same proportion across interventions and regions. If total 
costs fell below the national budget spending was scaled up until the budget was exhausted or the maximum 
coverage reached. This simulates the situation where there is central co-ordination that allows the transfer 
of funds between regions to support the provision of planned local investments.  
Under the contingency fund policy a proportion of the total HIV budget was set aside prior to development 
of the investment strategy (a 5% contingency fund was used as this generated the most health in this 
example, see Supplementary Appendix) to support provision of planned local investments when uncertainty 
unfolds. Decision makers planned to spend the total HIV budget less the amount dedicated to the 
contingency fund. Any intervention service experiencing costs that exceeded their allocated budget could 
use the contingency fund to preserve their planned coverage. If the contingency fund was insufficient to 
pay for all claims, each claim was reduced by the same proportion. Any contingency funds that were not 
required were assumed to be used ineffectively. This simulates a similar situation to the regional policy but 
whereby there is also a centrally co-ordinated fund to support provision of local investments.  
Figure 1: Policy response to uncertainty under current information 
 
RESULTS 
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HIV investment strategy based on current information  
The optimal coverage level for the interventions based on maximising expected health outcomes based on 
currently available information varies by region and national HIV budget (Figure 2). At low budgets 
investments focus on late ART as universal access is a priority. As budgets increase investment shifts to 
circumcision as this is the most cost-effective intervention.  At higher budgets investments in early ART 
start. Investments in early ART are initially focused on regions with a high prevalence and/or high baseline 
rate of circumcision, as observation of these features implies that a higher proportion of susceptible 
individuals are at risk of contracting HIV, reflecting difference in sexual behaviours across regions. The 
resulting higher transmission risk in these regions make the preventative effects of early ART particularly 
valuable.  For example, in the Northwestern province, the proportion of the population entering the 
circumcised group at model entry (baseline) is much higher than any of the other regions (36.3% vs <5% 
in other regions) ² see Table S1 of the Supplementary Appendix.  This means that to produce the observed 
prevalence level in 2013 for this region, the proportion of susceptible individuals at risk of contracting HIV 
is inferred to be relatively high. This makes early ART which is very effective at preventing transmission a 
better buy than circumcision in this region.  
 
Figure 2: Intervention coverage by region and budget.  
 
Maximum population health benefits from evidence generation 
activities 
We assessed the maximum expected value of improved information if this information were to become 
available before budgets are set and coverage decisions made. This maximum value can be estimated by 
comparing the health generated under perfect information to the health generated under current 
information. Perfect information improves health (Figure 3) since it ensures that planned programmes are 
fully tailored to the prevailing conditions and removes the need to modify planned programmes in response 
to uncertainty. The health gain achieved at a specific budget can be estimated as the vertical difference 
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between the current information and perfect information curves. At lower budgets there is little difference 
between perfect information and current information. This is because whilst universal access is a priority, 
the decision maker has little opportunity to respond to prevailing conditions as they are constrained to only 
invest in late ART and to provide even coverage across regions.1  
 
Figure 3: Health generated under current information (regional policy) and perfect information 
at a range of national HIV budgets.  
 
Reflecting the opportunity costs of evidence generation 
expenditures 
Improved information provides a means through which to improve population health (Figure 3). However, 
the difference between the health attained with perfect information and that attained with current 
information does not account for the impact on health of spending funds on research which could 
otherwise have been used to fund services. For example, at a HIV budget of $20 pcpa the health benefits 
of research are shown in Figure 4(a) as the vertical distance between points A and B. If the research costs 
$1 pcpa the remaining intervention budget is $19 pcpa and the net health gains of evidence generation, 
taking in to account research costs, are shown by the vertical distance between A and C. If the research 
costs $5 pcpa the remaining budget would be $15 pcpa.  
In this instance the intervention budget left over after research is sufficiently low that the health benefits 
of research are outweighed by the costs imposed and there is a net health loss which is the vertical distance 
between A and D.  
We are able to identify the point at which the health benefits of research are exactly the same as the costs 
so we would be indifferent as to whether the research went ahead or not, this is shown by point E. Point 
                                                          
1 At some budgets, it is actually possible for the current information policy to perform better than the perfect 
ŝŶĨŽƌŵĂƚŝŽŶƉŽůŝĐǇ ?dŚŝƐŽĐĐƵƌƐďĞĐĂƵƐĞǁĞĚŽŶŽƚ ?ĐŽŶƐƚƌĂŝŶ ?ƚŚĞƌĞŵĞĚŝĂůĂĐƚŝŽŶƐ ?Ğ ?Ő ? ?ǁĞĚŽŶŽƚƌĞƋƵŝƌĞ
equal coverage across regions. 
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E occurs at a budget of $17 pcpa when $3 pcpa has been spent on research. This $3 represents the maximum 
that could be spent on research before the net health effects become negative. This maximum monetary 
value of research can be estimated for any budget (Figure 4(b)). Although the health gains associated with 
perfect information level off at higher budgets (Figure 4(a)) the monetary value of research continues to 
rise (Figure 4(b)). This reflects the fact that the opportunity cost of health care funds are lower at higher 
budgets (there are fewer remaining high value investments to make) so we are willing to give up more 
budget to achieve similar health gains from research. The true monetary value of a specific evidence 
generation programme will be lower because uncertainty can only be reduced rather than eliminated (see 
Discussion). Therefore, the amount that can be spent on research whilst still generating population health 
benefits will also be lower. 
 
Figure 4: (a) Comparing the health gains of research to the health opportunity costs of research 
funding; and (b) The maximum that could be spent on research before reducing population 
health.  
 
The impact of budgetary policies on the value of evidence 
generation  
Under current information, a national policy response to uncertainty improves population health compared 
to a regional policy (Figure 5) as funds can be moved between regions and interventions to support planned 
intervention coverage levels as uncertainty is realised. Cost over-runs at planned coverage levels can be met 
by releasing funds from where there are cost under-runs at planned coverage levels, thus reducing the 
likelihood of substantial deviations from the original investment strategy. When the contingency fund policy 
operates the planned investment strategy is more likely to be delivered, but there is also a higher chance 
that the investment strategy is conservative and contingency funds are not used effectively. At some budgets 
the contingency fund performs worse than the regional policy. In these circumstances, the use of the 
contingency fund to support the delivery of late ART is not sufficient to offset the potential loss of health 
outcomes from unspent contingency funds. At higher budgets, the contingency fund generates more health 
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than the regional policy as although planned investment in early ART is lower, there is an increased 
likelihood that more cost-effective interventions ² circumcision and late ART ² are provided as planned.   
As the national and contingency fund policies generally improve the population health attained under 
current information, they reduce the gains in population health attainable via perfect information (Figure 
5). The flexibility afforded by these policies reduces the costs of uncertainty, and therefore the benefits 
achievable by eliminating uncertainty. This indicates that the value of evidence generation activities - and 
therefore the amount that should be invested in funding them - depends on the budgetary policy in place.  
 
Figure 5: Health generated under current information with the regional, contingency and 
national budgetary policies and perfect information at a range of national HIV budgets.  
 
DISCUSSION 
This work provides practical insights into the population health consequences of uncertainties in the 
evidence supporting health care decisions and the policy levers available to mitigate these. We show that 
the collection of further information to reduce uncertainty at the point at which the HIV investment 
strategy is being developed and budgets assigned has the potential to improve population health. Indeed, 
guidance issued by the World Health Organisation (WHO) and UNAIDS emphasises detailed collection of 
epidemiological data as an essential first step for informing the strategic direction of resources.33 We show 
that robust data can both improve the design of the investment strategy, and the likelihood that any planned 
investment strategy will actually be implemented. However, it is insufficient to quantify the potential health 
gains associated with improved data. Evidence is costly to generate, so the health opportunity costs imposed 
by investment in research rather than service delivery must be calculated to determine if research 
investments will result in a net improvement to population health. Finally we show that the health benefits 
of research will depend on the budgetary policy in place. The value of evidence generation is higher when 
restrictive budgetary policies are in place as these policies reduce the population health attained under 
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current information. This study used a case study in HIV but the findings are general to all situations in 
which resources are allocated to health care programmes and there is uncertainty relating to the costs and 
effects of those programmes. Although other studies have demonstrated the utility of methods for 
evaluating the value of evidence generation activities in the global health setting34, these studies have not 
attempted to incorporate decision makers responses to cost under- or over-runs, which can have important 
implications for how evidence generation activities are valued. The methods presented show how 
quantitative appraisal of evidence generation activities can be conducted. These methods can be used to 
support more accountable decision making amongst organisations charged with allocating limited funds to 
primary data collection efforts (e.g. trials, surveys) and secondary data analysis. 
Our results also suggest that in the face of uncertainty, the budgetary policy may represent an important 
policy lever through which to improve population health. For example, health gains may be achievable by 
moving from a regional to a national policy, though this would require a wider appraisal of the various 
costs and benefits of operating a more centralised system.  The budgetary policies presented were 
intended to represent the range of situations operating within low-income countries. For example, the 
regional policy reflects a decentralised system in which transfers of funds do not occur or are difficult to 
effect (for example, in Kenya, HIV and other health care resources are now allocated and controlled at 
county level13), the national policy reflects systems with more central co-ordination where re-allocations 
are feasible (e.g. via budget virements as used in Malawi) and the contingency policy reflects a situation 
that may operate informally or formally in some systems HJ´XQDOORFDWHGUHVHUYHVµas in Sierra Leone). 
These scenarios reflect our understanding of policy responses to uncertainty established via discussions 
with individuals with experience of national-level HIV resource allocation planning and delivery and 
individuals with research interests in public financial management. The policy scenarios include 
assumptions about how decision makers might respond to having more or less funds than required to 
meet their original coverage goals. If these assumptions do not hold then the results will change. For 
example, if decision makers with excess funds transfer these funds to productive uses within other health-
improving intervention programmes, then more health could be generated under current information, 
which reduces the benefits of evidence generation activities. A similar line of argument applies to the 
assumption that unused contingency funds are used ineffectively. If this is not the case and they are used 
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to fund other health-generating activities then this would increase the health generated under current 
information and reduce the value of further evidence generation activities. More formal qualitative and 
quantitative research is warranted to better characterise how resource allocation decisions respond to 
unfolding uncertainties.  
In this work we estimated the expected maximum value that could be derived from removing all uncertainty 
relating to a specific set of policy questions. Estimating the value of removing all uncertainty provides the 
starting point to determine whether additional data collection efforts are worthwhile. If the cost of potential 
new research activities exceeds the value of removing all uncertainty then further evidence generation is 
unlikely to be worthwhile. However, if this is not the case the next step would be to quantify the value of 
specific data collection activities which would be expected to reduce some uncertainties rather than 
completely eliminate all uncertainty. Evaluations of specific evidence generation activities should reflect the 
degree to which new data will reduce uncertainties, the value of resolving these uncertainties, the timeliness 
with which data can be collected and reported, whether commissioning research would have any 
implications for the HIV investment strategy today (e.g. it may not be possible to adopt an intervention 
whilst randomising individuals within a trial to that intervention), uncertain future changes in 
prices/technologies/the evidence base, decision makers response to new information and to cost over- and 
under-runs, any response by other actors to unfolding events (e.g. individuals seeking care in regions with 
better resource availability), the full set of constraints in place (e.g. constraints on feasible resource 
allocations, constraints on the availability of key inputs such as health care workers) and the costs and timing 
of collecting data (for example some data collection activities such as epidemiological surveys are generally 
conducted at regular intervals to provide up to date information).35, 36  For some types of evidence, value 
may extend beyond the policy questions considered, for example evidence on the relative effects of 
interventions may generalise across jurisdictions37. In such cases some estimate of the scale of these benefits 
will be required. Given the complexity and futility of attempting to formally model all of these 
considerations there is a need for pragmatic guidance on conducting quantitative assessments of evidence 
generation activities to inform real-time policy decisions.  
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CONCLUSION 
The development of a strategy for HIV investment, and in fact any investment in health care, relies on the 
availability of relevant and reliable evidence. This evidence and the process by which it is synthesised to 
support decision making are inherently subject to some level of uncertainty. We show that the collection 
of further information to reduce these uncertainties at the point at which an investment strategy is being 
developed and budgets assigned has the potential to improve population health. Better evidence can both 
improve the design of the investment strategy, and the likelihood that any planned investment strategy will 
actually be implemented, thus leading to health improvements in the same way as direct delivery of health 
care. However, as resources for health care and research are limited, the desirability of research expenditures 
should be assessed on the same basis as other health care resources, i.e. the health gains from research must 
be expected to exceed the health opportunity costs imposed as funds are diverted to research rather than 
service provision. Quantitative appraisals of evidence generation activities offer the opportunity to support 
a more accountable process for allocating health-related funding to evidence generation activities, and 
further pragmatic guidance on conducting these types of assessments in HIV and global health more 
generally is required.  
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FIGURES 
 
Figure 1: Policy response to uncertainty under current information 
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Figure 2: Intervention coverage by region and budget. Bar height represents the proportion of the 
maximum possible coverage achieved for each intervention. Maximum possible coverage is 80% of all 
individuals with CD4 counts below 350 for late ART, 40% of all individuals without HIV infection for 
circumcision (i.e. equivalent to 80% of all males as they make up half of the modelled population), and 
73% of all individuals with CD4 counts above 350 for early ART. Each row of bars represents 
investments in a region and moving from left to right shows the impact of budget expansion on the 
coverage level for each intervention.   
21 
 
 
Figure 3: Health generated under current information (regional policy) and perfect information 
at a range of national HIV budgets. The slope of each line represents the QALYs generated per $1 
spent on HIV. A kink in the current information curve occurs at the point at which full coverage for late 
ART is achieved and highly cost-effective circumcision is adopted. To the left of this point, the increases 
in health reflect expansion of late ART, while to the right of the point, the increases reflect expansion of 
early ART. No kink is observed in the perfect information curve as the national budget at which 
circumcision becomes affordable varies according to the investment plan made under each realisation of 
uncertainty. 
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Figure 4: (a) Comparing the health gains of research to the health opportunity costs of research 
funding; and (b) The maximum that could be spent on research before reducing population 
health.  
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Figure 5: Health generated under current information with the regional, contingency and 
national budgetary policies and perfect information at a range of national HIV budgets.  
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